# US 2001/0037025 A1 · New compounds, their preparation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0037025 A1
- Document ID: US20010037025A1
- Status: Published application
- Kind: A1
- Application number: 09/863,987
- Filed: 2001-05-23
- Published: 2001-11-01
- Earliest claimed: 1998-05-11
- Inventors: Anthony Murray; John Bondo Hansen
- Web page: https://patentgrep.com/patent/US20010037025A1

## CPC

- C07C 59/72: containing six-membered aromatic rings and other rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07C 57/50: containing condensed ring systems
- C07C 63/66: Polycyclic acids with unsaturation outside the aromatic rings
- C07C 65/26: containing rings other than six-membered aromatic rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel compounds of formula I 1 wherein R1, R2, W, Z and R5 to R9 are defined more fully in the description. The compounds are useful in the treatment of ailments and disorders where a reduction of the blood glucose is beneficial, such as diabetes.

## Claims

### Claim 1

A compound of formula I
12
wherein
R1 and R2 are independently hydrogen or C1-6 alkyl;
W is
13
, O, N—R3, S, SO or SO2 wherein R3 and R4 are independently hydrogen or C1-6 alkyl;
R5 is hydrogen, C1-6 alkyl, halogen, OR11, SR11, OCOR11, NH2, NHR11, NR11R12, NHCOR11, NR11—COR12 where R11 and R12 are independently C1-6 alkyl, phenyl or alkyl phenyl;
R6 is hydrogen, or taken together with R7 forms a double bond, or taken together with R7 is methylene to form a cyclopropyl ring;
R7 is hydrogen, or taken together with R6 forms a double bond, or taken together with R6 is methylene to form a cyclopropyl ring, or taken together with R9 forms a double bond, or taken together with R9 is methylene to form a cyclopropyl ring;
R8 is hydrogen, or taken together with R9 forms a double bond, or taken together with R9 is methylene to form a cyclopropyl ring
R9 is hydrogen, hydroxy, OR13, OCOR13, or taken together with R7 forms a double bond, or taken together with R7 is methylene to form a cyclopropyl ring, or taken together with R8 forms a double bond, or taken together with R8 is methylene to form a cyclopropyl ring, where R13 is C1-6 alkyl, phenyl or alkyl phenyl;
Z is X—Y—R10, wherein X is a valence bond, phenyl or pyridyl, optionally substituted with C1-3 alkyl, halogen, hydroxy, C1-3 alkoxy, C1-3 acyloxy, C1-3 alkyl halide, thiol, C1-3 substituted thiol, Y is C1-6-alkyl, C2-6 alkenyl or C2-6 alkynyl and R10 is CO2H, tetrazole, PO3H, SO3H, CO2R15, CONR16R17, CH2OH, CHO, CH2OR18, CH(OR19)2, HC(OR20O), COR21, CR20(OR19)2, CR21(OR20O), wherein R15 is C1-6 alkyl, phenyl or alkyl phenyl; or
Z is ═Y—R10, wherein Y is CR14, CR14—C1-6 alkyl, CR14phenyl, CR14pyridyl, CR14C1-3 alkylaryl, CR14—C2-5 alkenyl or CR14—C2-5 alkynyl, wherein R14 is H or C1-3 alkyl and R10 is CO2H, tetrazole, PO3H, SO3H, CO2R15, CONR16R17, CH2OH, CHO, CH2OR18, CH(OR19)2, HC(OR20O), COR21, CR20(OR19)2, CR21(OR20O), wherein R15 is C1-6 alkyl, phenyl or alkyl phenyl;
R16 and R17 are independently hydrogen, C1-6-alkyl, C5-8 cycloalkyl, phenyl or C1-6-alkyl phenyl; R18 is C1-6-alkyl, phenyl or C1-6-alkyl phenyl; R19 is C1-6 alkyl; R20 is C2-4 alkyl; R21 is C1-6 alkyl phenyl or C3-6 cycloalkyl;
or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, or any tautomeric forms.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein R5 is hydrogen or C1-6-alkyl.

### Claim 3 (depends on 1)

A compound according to claim 1 wherein W is
14
wherein R3 and R4 are independently C1-6 alkyl.

### Claim 4 (depends on 1)

A compound according to claim 1 wherein R6 taken together with R7 is methylene to form a cyclopropyl ring.

### Claim 5 (depends on 1)

A compound according to claim 1 wherein R6 and R7 are hydrogen.

### Claim 6 (depends on 1)

A compound according to claim 1 wherein R6 and R7 form a double bond.

### Claim 7 (depends on 1)

A compound according to claim 1 selected from the group consisting of
[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-acetic acid,
[5-(5,5,8,8-Tetramethyl-5,6;7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-acetic acid,
4-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidenemethyl]-benzoic acid,
4-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidenemethyl]-benzoic acid,
6-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidenemethyl]-nicotinic acid,
6-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidenemethyl]-nicotinic acid,
4-{2-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-ethyl}-benzoic acid,
4-{2-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-ethyl}-benzoic acid,
6-{2-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-ethyl}-nicotinic acid,
6-{2-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-ethyl}-nicotinic acid,
4-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-benzoic acid,
4-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-benzoic acid,
6-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-nicotinic acid,
6-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-nicotinic acid,
3-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-acrylic acid,
3-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-acrylic acid,
[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-propynoic acid,
[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-propynoic acid,
[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-acetic acid,
[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-acetic acid,
4-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidenemethyl]-benzoic acid,
4-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidenemethyl]-benzoic acid,
6-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidenemethyl]-nicotinic acid,
6-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidenemethyl]-nicotinic acid,
4-{2-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-ethyl}-benzoic acid,
4-{2-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-ethyl}-benzoic acid,
6-{2-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-ethyl}-nicotinic acid,
6-{2-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-ethyl}-nicotinic acid,
3-Methyl-4-[5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-but-2-enoic acid,
3-Methyl-4-[5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-ylidene]-but-2-enoic acid,
3-Methyl-4-[3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-but-2-enoic acid,
3-Methyl-4-[3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentylidene]-but-2-enoic acid,
3-{4-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-phenyl}-but-2-enoic acid,
3-{4-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-phenyl}-but-2-enoic acid,
3-{6-[5-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-pyridin-3-yl}-but-2-enoic acid,
3-{6-[5-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-en-2-yl]-pyridin-3-yl}-but-2-enoic acid,
3-{4-[4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-1-enyl]-phenyl}-but-2-enoic acid,
3-{4-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-1-enyl]-phenyl}-but-2-enoic acid,
3-{6-[4-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-1-enyl]-pyridin-3-yl}-but-2-enoic acid,
3-{6-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-1-enyl]-pyridin-3-yl}-but-2-enoic acid,
4-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-benzoic acid,
4-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-benzoic acid,
6-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-nicotinic acid,
6-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-nicotinic acid,
3-{4-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-phenyl}-but-2-enoic acid,
3-{4-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-phenyl}-but-2-enoic acid,
3-{6-[3-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-pyridin-3-yl}-but-2-enoic acid,
3-{6-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-pyridin-3-yl}-but-2-enoic acid,
4-[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-benzoic acid,
4-[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-benzoic acid,
6-[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-nicotinic acid,
6-[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-nicotinic acid,
[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-propynoic acid,
[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-propynoic acid,
3-[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-but-2-enoic acid,
3-[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopentyl]-but-2-enoic acid,
4-[2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-benzoic acid,
4-[2-Methoxy-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-benzoic acid,
6-[2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-nicotinic acid,
6-[2-Methoxy-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-nicotinic acid,
[2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-propynoic acid,
[2-Methoxy-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-propynoic acid,
3-[2-Methoxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-but-2-enoic acid,
3-[2-Methoxy-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-bicyclo[3.1.0]hex-2-yl]-but-2-enoic acid,
4-[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-benzoic acid,
4-[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-benzoic acid,
6-[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-nicotinic acid,
6-[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-nicotinic acid,
[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-propynoic acid,
[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-propynoic acid,
3-[1-Methoxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-but-2-enoic acid, and
3-[1-Methoxy-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopent-2-enyl]-but-2-enoic acid
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A compound according to claim 1 which acts as a Retinoid X Receptor (RXR) agonist.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising, as an active ingredient, an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

### Claim 10 (depends on 9)

The composition according to claim 9 in unit dosage form, comprising from about 0.05 to about 100 mg of the compound or pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 9)

The pharmaceutical composition according to claim 9 for oral, nasal, transdermal, pulmonal, or parenteral administration.

### Claim 12 (depends on 1, 7)

A method for the treatment of non-insulin dependent diabetes mellitus, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1 or the composition of claim 7.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the effective amount of the compound is in the range of from about 0.05 to about 100 mg per day.
